These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17661736)

  • 21. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
    Hawkey CJ; Weinstein WM; Stricker K; Murphy V; Richard D; Krammer G; Rebuli R
    Aliment Pharmacol Ther; 2008 May; 27(9):838-45. PubMed ID: 18221410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
    Kyle C; Zachariah J; Kinch H; Ellis G; Andrews C; Adekunle F
    Int J Clin Pract; 2008 Nov; 62(11):1684-92. PubMed ID: 19143855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
    Mackenzie IS; Wei L; Macdonald TM
    Eur J Clin Pharmacol; 2013 Feb; 69(2):133-41. PubMed ID: 22732767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS
    Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
    Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe acute liver injury associated with lumiracoxib.
    Pillans PI; Ghiculescu RA; Lampe G; Wilson R; Wong R; Macdonald GA
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1102-5. PubMed ID: 22142375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
    Schnitzer TJ; Gitton X; Jayawardene S; Sloan VS
    Curr Med Res Opin; 2005 Jan; 21(1):151-61. PubMed ID: 15881487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
    Farkouh ME; Verheugt FW; Ruland S; Kirshner H; Jeger R; Gitton X; Krammer G; Stricker K; Sallstig P; Mellein B; Matchaba P; Chesebro JH
    J Clin Hypertens (Greenwich); 2008 Aug; 10(8):592-602. PubMed ID: 18772641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
    Schnitzer TJ; Dattani ID; Seriolo B; Schneider H; Moore A; Tseng L; Sallstig P; Rebuli R; Maxwell T
    Clin Rheumatol; 2011 Nov; 30(11):1433-46. PubMed ID: 21607551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 34. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D
    MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
    Felden L; Walter C; Angioni C; Schreiber Y; von Hentig N; Ferreiros N; Geisslinger G; Lötsch J
    Pharm Res; 2014 Jul; 31(7):1813-22. PubMed ID: 24469906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
    Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.